Thermo Fisher Scientific's B•R•A•H•M•S earned FDA clearance for expanded use of the B•R•A•H•M•S PCT sensitive KRYPTOR assay.
Here are four points:
1. The B•R•A•H•M•S PCT sensitive KRYPTOR assay is designed to assist clinicians as they decide if a patients needs antibiotic therapy for lower respiratory tract infections.
2. The assay also helps clinicians decide when to stop giving antibiotics to patients with LRTI and sepsis.
3. With the clearance, clinicians in emergency departments, intensive care and other hospital units now have access to an antibiotic stewardship tool.
4. The B•R•A•H•M•S PCT sensitive KRYPTOR has decreased LRTI patient antibiotic prescription rate and duration.
"We are thrilled that the FDA has expanded the use of B•R•A•H•M•S PCT sensitive KRYPTOR to include antibiotic therapy decision-making," said Patrick Durbin, senior vice president and president of specialty diagnostics at Thermo Fisher Scientific. "Clinicians in the U.S. now have an important tool to support their antibiotic stewardship efforts, benefiting their patients as well as the community at large."
